RenovaCare products are under development and not approved for sale in the United States.

Results may vary from person to person.

RenovaCare products are under development and not approved for sale in the United States.
Results may vary from person to person.

RenovaCare to Present at H.C. Wainwright Global Life Science Conference March 9-10, 2021

Roseland, NJ – February 25th, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced today that the Company will present at the 2021 H.C. Wainwright Global Life Sciences Conference, scheduled for March 9 – 10.

RenovaCare to Present at Noble Capital Markets Annual Investor Conference on January 19, 2021

Roseland, NJ – January 19, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced today that the Company will present at NobleCon17 – Noble Capital Markets’ Seventeenth Annual Investor Conference on Tuesday, January 19 at 5:15pm EST. The conference is virtual, with no cost, obligation or restrictions to attend: www.noblecon17.com.

RenovaCare Chairman Discusses 2020 Highlights and Provides 2021 Outlook

Roseland, NJ – December 22, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced today that it has issued the following year-end letter from its Chairman and CEO, Alan L. Rubino to the Company’s stockholders and interested parties:

RenovaCare Awarded New Patents Allowing Greater Versatility of SkinGun™; Sterility in Field Environments; Spray Solutions to Now Include Targeted Cells, Drugs or Hormones

Roseland, NJ – November 19, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced the issuance of two new patents encompassing improvements to the SkinGun™, expanding its potential application beyond the surgical setting into the field, and allowing the use of liquid suspension solutions to include drugs, hormones, and other useful agents.

RenovaCare to Commence Investor Business and Financial Presentations; Webcast on October 29, 2020

Roseland, NJ – October 5, 2020 – RenovaCare, Inc. (Symbol: RCAR), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that Alan L. Rubino, Chief Executive Officer and President, has been elected to the additional role of Chairman of the Board of RenovaCare effective October 1, 2020.

RenovaCare to Present at BioNJ/JP Morgan/J&J BioPartnering Conference

Roseland, NJ – September 15, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the Company will present at the tenth annual BioPartnering Conference, hosted by BioNJ and co-sponsored by J.P. Morgan and Johnson & Johnson Innovation, scheduled for October 6 – 7, 2020.

RenovaCare Receives FDA Conditional IDE Approval of CellMist™ System and SkinGun™ Device, Enabling Clinical Study for Safety and Feasibility

Roseland, NJ – August 11, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the US Food and Drug Administration (FDA) conditionally approved the Company’s Investigational Device Exemption (IDE) application to conduct a clinical trial to evaluate the safety and feasibility of autologous stem cells rendered by its CellMist™ System from donor skin and applied topically with the SkinGun™ spray device for treatment of burn wounds.